Compare · AVTR vs BNGO
AVTR vs BNGO
Side-by-side comparison of Avantor Inc. (AVTR) and Bionano Genomics Inc. (BNGO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTR and BNGO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- AVTR is the larger of the two at $7.56B, about 572.7x BNGO ($13.2M).
- Over the past year, AVTR is down 10.3% and BNGO is down 67.0% - AVTR leads by 56.6 points.
- AVTR has hit the wire 3 times in the past 4 weeks while BNGO has been quiet.
- AVTR has more recent analyst coverage (25 ratings vs 5 for BNGO).
- Company
- Avantor Inc.
- Bionano Genomics Inc.
- Price
- $11.06-1.78%
- $1.15-0.86%
- Market cap
- $7.56B
- $13.2M
- 1M return
- +15.45%
- -0.86%
- 1Y return
- -10.34%
- -66.95%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2018
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 5
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Bionano Genomics Inc.
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes. Its Saphyr system includes an instrument, chip consumables, reagents, a suite of data analysis tools, and genome analysis services for researchers to evaluate optical genome mapping data. The company's Bionano prep kits and labeling kits provide the reagents and protocols needed to extract and label ultra-high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. Bionano Genomics, Inc. has a procurement and collaboration agreement with NuProbe, Inc. for research and product development in the fields of reproductive health and oncology liquid biopsies. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Latest AVTR
- Avantor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
- Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
- Bernstein resumed coverage on Avantor with a new price target
- President, VWR Dist. & Servs. Walker Corey covered exercise/tax liability with 3,010 shares, decreasing direct ownership by 0.78% to 384,535 units (SEC Form 4) to cover taxes
- Wolfe Research resumed coverage on Avantor with a new price target
- SEC Form SD filed by Avantor Inc.
- Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
- RBC Capital Mkts resumed coverage on Avantor with a new price target
- Avantor Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Latest BNGO
- Bionano Genomics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Bionano Announces Hiring of Chief Scientific Officer
- Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption
- Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders
- Bionano Genomics Inc. filed SEC Form 8-K: Leadership Update
- GENERAL COUNSEL Dixon Jonathan V. covered exercise/tax liability with 24 shares, decreasing direct ownership by 9% to 239 units (SEC Form 4) (for withholding tax)
- CHIEF OPERATING OFFICER Oldakowski Mark covered exercise/tax liability with 27 shares, decreasing direct ownership by 3% to 868 units (SEC Form 4) to satisfy withholding tax
- CHIEF MEDICAL OFFICER Chaubey Alka covered exercise/tax liability with 24 shares, decreasing direct ownership by 4% to 620 units (SEC Form 4) (for withholding tax)
- Principal Accounting Officer Adamchak Mark covered exercise/tax liability with 7 shares, decreasing direct ownership by 3% to 253 units (SEC Form 4) (withholding obligation)
- Bionano Genomics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits